Increasing Clinical Approvals Showing Promising Future
Rising cancer incidence has been driving the monoclonal antibody approvals at a high pace. Moreover, the potential of oncology market has prompted market players to concentrate more on R & D of cancer mAbs. Approximately 50% of the monoclonal antibodies are relevant to cancer therapies of total monoclonal pipeline. The market has vast array of clinical approvals which led to significant entry of pharmaceutical giants. A lot of FDA approvals are in market and a lot more are in phase...
View full press release